Erratum to: The Idiopathic Intracranial Hypertension Treatment Trial: A Review of the Outcomes (Headache: The Journal of Head and Face Pain, (2017), 57, 8, (1303-1310), 10.1111/head.13144)

The following statement was incorrect: The mean improvement was significantly greater in the acetazolamide group than the placebo group (acetazolamide 1.43 dB, from −3.53 dB at baseline to −2.10 dB at 6 months; placebo 0.71 dB, from −3.53 dB at baseline to −2.82 at 6 months; treatment effect 0.71 dB; 95% confidence interval (CI) 0–1.43 dB, P = 0.50). PMD in the fellow eye also showed greater improvement in the acetazolamide group (acetazolamide 0.87 dB, from −2.28 dB to −1.41 dB; placebo 0.42 dB, from −2.28 dB to −1.86 dB; treatment effect 0.44 dB; 95% CI 0.01–0.87 dB, P = 0.45). The correct statement should read (corrected text is in bold): The mean improvement was significantly greater in the acetazolamide group than the placebo group (acetazolamide 1.43 dB, from −3.53 dB at baseline to −2.10 dB at 6 months; placebo 0.71 dB, from −3.53 dB at baseline to −2.82 at 6 months; treatment effect 0.71 dB; 95% confidence interval (CI) 0–1.43 dB, P = 0.050). PMD in the fellow eye also showed greater improvement in the acetazolamide group (acetazolamide 0.87 dB, from −2.28 dB to −1.41 dB; placebo 0.42 dB, from −2.28 dB to −1.86 dB; treatment effect 0.44 dB; 95% CI 0.01–0.87 dB, P = 0.045).